1. Fig. 5 Nec-1 therapy decreases atherosclerotic lesion progression and markers of instability in Apoe−/− mice.
Nec-1 therapy decreases atherosclerotic lesion progression and markers of instability in Apoe−/− mice. (A) Apoe−/− mice were fed a Western diet for 6 weeks before implantation of time-release pellets containing placebo or Nec-1s (2 mg/kg per day). After four additional weeks of Western diet feeding, the mice were harvested for morphometric analysis of atherosclerosis. (B) En face lesion area was measured in placebo- and Nec-1s–treated mice and is represented as lesion area as a percentage of total aorta area. (C) Lesion area in the aortic sinus in placebo- and Nec-1s–treated mice is represented as total area in μm2. (D) Necrotic core area within aortic sinus lesions. (E to G) Immunohistochemical staining of smooth muscle-α actin (SMC marker) (E), CD68 (macrophage marker) (F), and pMLKL (G) was performed on aortic sinus lesions and quantified with ImageJ. Representative images per group are shown. AU, arbitrary units. (H) Serum IL-1β in mice from placebo- or Nec-1–treated groups was measured at sacrifice by enzyme-linked immunosorbent assay (ELISA). *P ≤ 0.05, **P < 0.01 by Student’s t test.
Denuja Karunakaran et al. Sci Adv 2016;2:e
Copyright © 2016, The Authors